JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevanceSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor inRead More
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
